Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure
2022 · Dermatology and Therapy · 30 citations
https://doi.org/10.1007/s13555-022-00743-9
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
7
Papers
90
Citations
4
h-index
3
i10-index
Ana P. Accioly is an academic researcher from Eli Lilly (United States). The author has contributed to research in topics: Psoriasis: Treatment and Pathogenesis & Asthma and respiratory diseases & Dermatology and Skin Diseases. The author has an h-index of 4, co-authored 6 publications.
https://doi.org/10.1007/s13555-022-00743-9
https://doi.org/10.1136/annrheumdis-2021-222027
Click to start Chat